Farther Finance Advisors LLC Has $689,000 Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Farther Finance Advisors LLC significantly increased its stake in Becton, Dickinson and Company by 98.7%, owning 4,000 shares valued at $689,000 as of the latest quarter.
• Analyst upgrades for Becton, Dickinson include a price target increase from $220.00 to $230.00 by Argus and several analysts giving it a "buy" rating.
• The company announced a quarterly dividend of $1.04 per share, with a dividend yield of 2.3%, to be paid on September 30th.

Farther Finance Advisors LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 98.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,000 shares of the medical instruments supplier's stock after buying an additional 1,987 shares during the period. Farther Finance Advisors LLC's holdings in Becton, Dickinson and Company were worth $689,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Northcape Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after purchasing an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after buying an additional 53 shares during the period. Brady Family Wealth LLC increased its stake in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock valued at $989,000 after buying an additional 53 shares during the period. Diversified Trust Co raised its holdings in Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after purchasing an additional 53 shares during the last quarter. Finally, Horizon Bancorp Inc. IN raised its holdings in Becton, Dickinson and Company by 10.9% during the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier's stock worth $130,000 after purchasing an additional 56 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent research reports. Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday. They issued a "sector perform" rating and a $211.00 price objective on the stock. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Finally, Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $213.09.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $184.59 on Friday. The company has a market capitalization of $52.91 billion, a PE ratio of 33.20, a PEG ratio of 1.46 and a beta of 0.27. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock's fifty day simple moving average is $188.27 and its 200 day simple moving average is $188.97.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is 74.82%.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock worth $551,536 in the last quarter. 0.36% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.